S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
Positive News Sentiment  
NASDAQ:TCRR

TCR2 Therapeutics - TCRR Stock Forecast, Price & News

$1.48
+0.10 (+7.25%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.37
▼
$1.48
50-Day Range
$0.83
▼
$1.48
52-Week Range
$0.82
▼
$3.88
Volume
175,131 shs
Average Volume
228,762 shs
Market Capitalization
$57.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.75

TCR2 Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
626.4% Upside
$10.75 Price Target
Short Interest
Healthy
3.50% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.65
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$83,594 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.18) to ($2.16) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.98 out of 5 stars

Medical Sector

15th out of 1,049 stocks

Biological Products, Except Diagnostic Industry

4th out of 170 stocks

See Top Rated MarketRank™ Stocks Here

TCRR stock logo

About TCR2 Therapeutics (NASDAQ:TCRR) Stock

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.

Receive TCRR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCRR Stock News Headlines

January 18, 2023 | reuters.com
TCRR.C - | Stock Price & Latest News | Reuters
January 9, 2023 | markets.businessinsider.com
SVB Securities Keeps Their Hold Rating on TCR2 Therapeutics (TCRR)
January 29, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
January 5, 2023 | finance.yahoo.com
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 5, 2023 | finance.yahoo.com
TCR² Therapeutics Announces Pipeline Priorities for 2023
January 2, 2023 | uk.finance.yahoo.com
TCR2 Therapeutics Inc. (TCRR)
December 16, 2022 | seekingalpha.com
TCRR TCR2 Therapeutics Inc.
November 23, 2022 | finance.yahoo.com
TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference
January 29, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
November 11, 2022 | finance.yahoo.com
Down 16.6% in 4 Weeks, Here's Why You Should You Buy the Dip in TCR2 Therapeutics Inc. (TCRR)
November 8, 2022 | finanznachrichten.de
TCR2 Therapeutics: TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 8, 2022 | finance.yahoo.com
TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 7, 2022 | finance.yahoo.com
TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of Cancer
November 6, 2022 | finance.yahoo.com
Is TCR2 Therapeutics (NASDAQ:TCRR) In A Good Position To Deliver On Growth Plans?
September 28, 2022 | finance.yahoo.com
TCR2 Therapeutics Shares Jump After Additional Reponses in Ovarian Cancer, Mesothelioma
September 28, 2022 | seekingalpha.com
TCR2 Therapeutics stock rises 16% as cell therapy for solid tumors shows promise in trial
September 28, 2022 | finance.yahoo.com
gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma
September 27, 2022 | finance.yahoo.com
TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors
September 26, 2022 | finance.yahoo.com
TCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
August 19, 2022 | seekingalpha.com
TCR² Therapeutics: Betting On A Solid Reversal
August 8, 2022 | finance.yahoo.com
TCR² Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 8, 2022 | finance.yahoo.com
What Kind Of Shareholders Hold The Majority In TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) Shares?
August 8, 2022 | americanbankingnews.com
TCR2 Therapeutics Inc. (NASDAQ:TCRR) Given Average Rating of "Moderate Buy" by Brokerages
June 27, 2022 | marketwatch.com
TCR2 Therapeutics Names Eric Sullivan Chief Financial Officer >TCRR
June 27, 2022 | finance.yahoo.com
TCR² Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial Officer
May 30, 2022 | finance.yahoo.com
Will TCR2 Therapeutics (NASDAQ:TCRR) Spend Its Cash Wisely?
May 12, 2022 | finance.yahoo.com
TCR² Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
See More Headlines
Receive TCRR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCRR Company Calendar

Last Earnings
11/08/2022
Today
1/29/2023
Next Earnings (Estimated)
3/28/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCRR
CUSIP
N/A
CIK
1750019
Web
www.tcr2.com
Phone
(617) 949-5200
Fax
N/A
Employees
137
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.75
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+626.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-99,810,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-49.52%
Return on Assets
-38.79%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.02
Quick Ratio
5.02

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.36 per share
Price / Book
0.20

Miscellaneous

Outstanding Shares
38,660,000
Free Float
28,989,000
Market Cap
$57.22 million
Optionable
Not Optionable
Beta
1.75

Key Executives

  • Garry E. Menzel
    President, Chief Executive Officer & Director
  • Peter Olagunju
    Chief Operating Officer
  • Eric M. Sullivan
    Chief Financial Officer
  • Alfonso Quintás-Cardama
    Chief Medical Officer
  • Praveen Malhotra
    Vice President-Information Technology

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













TCRR Stock - Frequently Asked Questions

Should I buy or sell TCR2 Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TCRR shares.
View TCRR analyst ratings or view top-rated stocks.

What is TCR2 Therapeutics' stock price forecast for 2023?

4 equities research analysts have issued 1 year price targets for TCR2 Therapeutics' stock. Their TCRR share price forecasts range from $2.00 to $18.00. On average, they expect the company's stock price to reach $10.75 in the next twelve months. This suggests a possible upside of 626.4% from the stock's current price.
View analysts price targets for TCRR or view top-rated stocks among Wall Street analysts.

How have TCRR shares performed in 2023?

TCR2 Therapeutics' stock was trading at $0.9988 at the beginning of 2023. Since then, TCRR shares have increased by 48.2% and is now trading at $1.48.
View the best growth stocks for 2023 here.

When is TCR2 Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our TCRR earnings forecast.

How were TCR2 Therapeutics' earnings last quarter?

TCR2 Therapeutics Inc. (NASDAQ:TCRR) issued its earnings results on Tuesday, November, 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.83) by $0.04.

What other stocks do shareholders of TCR2 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI).

When did TCR2 Therapeutics IPO?

(TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

What is TCR2 Therapeutics' stock symbol?

TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

How do I buy shares of TCR2 Therapeutics?

Shares of TCRR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TCR2 Therapeutics' stock price today?

One share of TCRR stock can currently be purchased for approximately $1.48.

How much money does TCR2 Therapeutics make?

TCR2 Therapeutics (NASDAQ:TCRR) has a market capitalization of $57.22 million. The company earns $-99,810,000.00 in net income (profit) each year or ($3.09) on an earnings per share basis.

How many employees does TCR2 Therapeutics have?

The company employs 137 workers across the globe.

How can I contact TCR2 Therapeutics?

TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The official website for the company is www.tcr2.com. The company can be reached via phone at (617) 949-5200 or via email at investors@tcr2.com.

This page (NASDAQ:TCRR) was last updated on 1/29/2023 by MarketBeat.com Staff